Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CanStem111P
A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- NCT02993731 ↗
- Completed
- Sumitomo Pharma America, Inc.
- Focused
We haven't built an HCP commentary report on CanStem111P (napabucasin in previously untreated metastatic pancreatic adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CanStem111P so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Carcinoma, Pancreatic Ductal
- Interventions
- Napabucasin; Nab-paclitaxel; Gemcitabine
- Arms
- Arm 1: Napabucasin plus Nab-paclitaxel with Gemcitabine · Experimental
- Arm 2: Nab-paclitaxel with Gemcitabine · Active comparator
- Enrollment
- 1,134
- Primary outcomes
- Overall Survival
- Sponsor
- Sumitomo Pharma America, Inc.
- Start
- Dec 2016
- Primary completion
- Mar 2020
- Results posted
- Yes
- Registry record
- NCT02993731 · updated Nov 15, 2023